Payer+Provider's Health System Review
Extended exclusivity for cancer treatment could cost public $3B: 6 notes
Pharma to Congress: ‘Quick fixes’ and ‘outrageous solutions’ to lower drug prices will jeopardize innovation
February 26, 2019
Read the full post on Becker's Hospital Review
